Cynata Therapeutics ended September with just A$175,000 in cash after a A$1.316 million quarterly operating drain, but says sweeping cuts and fresh funding could extend its runway into FY2028. The biotech has now reduced its workforce to zero, repaid its R&D loan and shifted focus to finding value for its Cymerus platform.
- A$175,000 cash at 30 September after A$1.316 million quarterly operating outflows
- All employee positions made redundant and outsourced trial work suspended or terminated
- A$1.694 million R&D tax refund received after quarter end, with A$1.067 million left after loan repayment
- Fully underwritten A$913,000 entitlement offer supports the proposed runway extension
- Board assessing licensing, partnering and new asset opportunities for Cymerus
Cynata cuts its way from a 0.13-quarter cash position
Cynata Therapeutics Limited (ASX:CYP) finished the September quarter with only A$175,000 in cash after burning A$1.316 million on operations. On the ASX’s mechanical funding calculation, that represented just 0.13 quarters of available funding, a figure that captures the biotech’s precarious position at quarter end.
The company says that number is not a reliable guide to its future cash needs because the quarter included one-off payments and a sharp restructuring. Every employee position was made redundant, including the chief executive and managing director role, while outsourced work connected to the Phase 2 acute graft versus host disease trial was suspended or terminated as far as possible. Directors also waived their fees from 1 July to 31 October.
Tax refund and entitlement offer rebuild liquidity
Cynata’s balance sheet has improved since the quarter closed. It received a A$1.694 million research and development tax incentive refund on 7 October and used part of it to repay its A$600,000 R&D-backed loan. The net proceeds from that refund were A$1.067 million, leaving the company with no further obligations to the lender.
The company is also pursuing a fully underwritten A$913,000 pro-rata renounceable entitlement offer. The three-for-eight entitlement offer is intended to provide another funding bridge, although the proposed FY2028 runway depends on both the capital raise and the lower spending base being sustained. Cynata has also terminated its At-the-Market Subscription Deed with Acuity Capital, removing that standby equity facility from its financing toolkit.
Clinical spending gives way to strategic review
The financial retrenchment follows the company’s June announcements on its Phase 2 aGvHD and CYP-004 osteoarthritis trials. Cynata says the Board is now evaluating future development pathways for its Cymerus platform, a technology it describes as a scalable method for manufacturing mesenchymal stromal cells from a single consistent cell source.
That review could involve seeking opportunities to realise value from Cymerus while obtaining rights to new assets. The filing does not identify a transaction, partner or asset under negotiation, so the immediate investment case rests more on preserving the platform and extending time than on a disclosed commercial catalyst.
Board changes add another layer of uncertainty
Governance is also in flux. Dr Paul Wotton is due to resign as a director at the conclusion of Cynata’s 25 November annual general meeting, while Dr Kilian Kelly remains on the Board as a non-executive director after leaving the chief executive and managing director role. The quarter included A$273,000 of related-party payments, which Cynata said comprised salary and termination payments to the former managing director.
The next test is whether the reduced operating model can preserve Cymerus long enough for the Board’s strategic review to produce a concrete path. A longer runway may buy time, but it does not by itself resolve the question of what the platform can be worth outside Cynata’s now much smaller organisation.
Bottom Line?
Cynata has bought time through restructuring, tax proceeds and a small equity raise, but the central value question for Cymerus remains unanswered.
Questions in the middle?
- How much cash will remain after the entitlement offer and the company’s post-restructuring operating costs are established?
- Can Cynata identify a licensing, partnering or asset transaction for Cymerus before the new runway is consumed?
- What strategic direction will emerge after the November AGM and Dr Wotton’s departure from the Board?